ClinicalTrials.gg
Active, not recruitingNCT06061718Updated Jun 3, 2024

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

A Phase 3 interventional study of iDose TR in Open Angle Glaucoma and Ocular Hypertension, sponsored by Glaukos Corporation. Active, not recruiting at 1 site in Armenia. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
33rd of 45
60 · median 135
Started
2023
the only one that year
Phase 3
16 of 46
none open now
Registered
43rd of 46
by date
Lead sponsor
7 of 46
Glaukos Corporation

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 33rd largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2023, is one of 16 in phase 3, and was the 43rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age-related cataract eligible for phacoemulsification in the study eye
  • open-angle glaucoma or ocular hypertension in the study eye
  • successful, uncomplicated cataract surgery using small incision phacoemulsification cataract surgery and insertion of a foldable posterior chamber IOL

Exclusion criteria

Exclusion Criteria:

  • unmedicated (washed out) IOP of >36 mmHg in the study eye
  • to travoprost or any other components of the travoprost intraocular implant
  • vertical cup/disc ratio > 0.8 in the study eye
  • best spectacle corrected visual acuity of worse than 20/80 in the fellow eye
  • any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    iDose TR

    Travoprost Intraocular Implant administered intracamerally in the study eye at the Day 1 Visit following successful cataract surgery

    Drug: iDose TR

Interventions

  • anchored intracameral implant containing travoprost

    Also known as: travoprost intraocular implant

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean diurnal IOP

    Mean diurnal IOP at the Month 3 Visit minus the mean diurnal IOP at the Baseline Visit

    Time frame: 3 months

07

Study locations

1 site
  • Glaukos Clinical Study Site
    Yerevan, Armenia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2024, 6 months.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 6 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Sep 29, 2023
StartActual
Sep 11, 2023
Primary completionActual
Mar 18, 2024
CompletionEst.
Dec 20, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06061718
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Sep 11, 2023
Primary completion
Mar 18, 2024
Completion
Dec 20, 2024 (estimated)
Last update
Jun 3, 2024

Study contacts

Study Director
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion